• Not yet recruiting

NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for RRMM After BCMA CAR-T Thaerapy

Updated: May 25


NCT04541368: Phase 1: A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy


cs1cart

A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy


Sponsor

Zhejiang University


Collaborator

Yake Biotechnology Ltd.


Chinese Study

 

ClinicalTrials.gov Identifier: NCT04541368


Official Title: Clinical Trial for the Safety and Efficacy of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy


First Posted: September 9, 2020


Click here to see details on ClinicalTrials.gov

 

Drug: CS1 Targeted CAR T-cells

 

CS1-CAR T Therapy

CS1-CAR T Therapy (Code C155800)

CS1-CAR T Infusion

CS1-CAR T Therapy

CS1-CAR T-cell Therapy



CS1-CAR T-cells

Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-cells (Code C160711)

Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-cells

Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched Autologous T-lymphocytes

Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-cells

Autologous Anti-CS1 Hinge-optimized CAR-4-1BB-EGFRt-expressing Memory-enriched T-lymphocytes

CS1-CAR T-cells

CS1-CAR T-lymphocytes

 

Location

China, Zhejiang





Posts Archive